Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era

Objectives: Tocilizumab (TCZ), an IL-6 receptor antagonist, is used in the treatment of severe COVID-19 caused by infection with SARS-CoV-2. However, unintended consequences of TCZ therapy include reactivation of tuberculosis (TB) or hepatitis B virus (HBV), and worsening of hepatitis C virus (HCV)....

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Cori, Andersson, Monique I., Ansari, M. Azim, Moswela, Olivia, Misbah, Siraj A., Klenerman, Paul, Matthews, Philippa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417527/
https://www.ncbi.nlm.nih.gov/pubmed/34490299
http://dx.doi.org/10.3389/fmed.2021.706482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417527/
https://www.ncbi.nlm.nih.gov/pubmed/34490299
http://dx.doi.org/10.3389/fmed.2021.706482

Ejemplares similares